OncoC4 Receives FDA Fast Track for Cesalatamig
Rockville, Maryland, USA, September 16, 2026 OncoC4, Inc. has announced that the U.S. Food and Drug Administration (FDA) has...
narcolepsy
Advertisement
Viatris WAKIX Approved in Japan for Sleep Disorders
Tokyo, Japan, September 16, 2026 Viatris Inc. announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved...
Harmony Biosciences Reports Record Q2 2026 Revenue, Shares Positive BP-205 Phase 1 Data
PLYMOUTH MEETING, Pa., August 4, 2026 Harmony Biosciences reported record second-quarter 2026 net revenue of $261.3 million for WAKIX®...
Lilly Completes Centessa Deal to Accelerate Treatments for Narcolepsy and Sleep-Wake Disorders
INDIANAPOLIS, June 24, 2026 Eli Lilly and Company announced the successful completion of its acquisition of Centessa Pharmaceuticals plc,...
Dimerix Licenses DMX-200 to Everest Medicines in Asia
MELBOURNE, Australia, June 16, 2026 Dimerix Limited has announced a landmark exclusive licensing agreement with Everest Medicines for the...
Advertisements
Jazz Presents New Xywav Data at SLEEP 2026 Meeting
DUBLIN, Ireland, June 16, 2026 Jazz Pharmaceuticals plc has unveiled extensive late-breaking research at SLEEP 2026, presenting 11 new...
Jazz Highlights New Xywav Data Across Narcolepsy and Idiopathic Hypersomnia
DUBLIN, Ireland, June 4, 2026 Jazz Pharmaceuticals has announced the presentation of an extensive portfolio of new clinical and...
Alkermes Reports Strong Phase 2 Data for Narcolepsy Drug
DUBLIN, April 16, 2026 Alkermes plc has announced new data from its Vibrance-1 Phase 2 clinical study of alixorexton,...
Alkermes Expands Sleep Portfolio With Avadel Buy
DUBLIN, Feb. 12, 2026 — Alkermes plc has completed its acquisition of Avadel Pharmaceuticals plc, accelerating its strategic entry...
Axsome Advances AXS-12 Toward NDA for Narcolepsy
NEW YORK | December 31, 2025 — Axsome Therapeutics announced it has received formal FDA pre–New Drug Application (Pre-NDA)...
Advertisement
